Barcelona – Pittsburgh
Thank you for joining the XII Biennial Conference Barcelona-Pittsburgh!
This conference has become a reference in the field of dementia. On June 2022, BCNPIT emerged again as a valuable forum where professionals from all over the globe connected and shared their work and prospects about dementia.
This high-quality conference brought together panellists of recognized international scientific prestige and created and interactive space related to neuroscience which ultimate objective was to benefit the people affected and their families.
See you all at Barcelona-Pittsburgh 2024!
Speakers of the BCNPIT 2022
Currently, Dr. Costa is Director of Plasma Proteins Research of the Grifols Bioscience Research Group, where she is in charge of leading Alzheimer’s Disease research.
Montse Costa, PhD Director of the Plasma Proteins Research at the R&D GrifolsHead Neurodegeneration Development Unit at Biogen
Samantha Budd Haeberlein Head Neurodegeneration Development Unit at BiogenClinical Research Sr Manager at Araclon Biotech
Elisabet Molina, MSc Clinical Research Sr Manager at Araclon BiotechHe is particularly interested in bridging biomedical research with drug development by adapting novel technologies to target identification/validation- and screening programs.
Alfredo Cabrera, PhD Senior Scientist at JanssenDr. Montaner’s clinical and laboratory work focuses on the identification of biomarkers to be used as diagnostic and prognostic tools in ischemic and haemorrhagic stroke and also as companion diagnostics for several stroke therapies.
Joan Montaner Director of the Stroke Program at the Institute of Biomedicine of Seville (IBiS)At Ace, he design CTs and other global CT from pharmaceutical companies, participate in international boards to improve CT management and promote research projects to validate novel biomarkers for an early detection of the disease and find novel therapeutical approaches.
Xavier Morató, PhD Pharmacy Unit at AceThe main focus of Prof. Ramirez research is the identification of the molecular genetic mechanisms which underlie cognitive disorders including neurodegenerative dementias such as Alzheimer’s disease.
Prof. Alfredo Ramírez, MD, PhD Professor for Neurogenetics of Cognitive disorders at the University Hospital CologneAs a clinician he has a longstanding expertise in translational research, focusing on how to improve individual diagnostics and therapy of disorders of the nervous system and how to define most reliable brain activations in pathological brains.
Roland Beisteiner, MD Associate Professor the Medical University of ViennaProf. Arcadi Navarro, biologist, ICREA professor and researcher at the Department of Experimental and Health Sciences at UPF, Director of the Pasqual Maragall Foundation and Barcelonaβeta Brain Research Center
Arcadi Navarro, PhD Director at Fundación Pasqual MaragallIn addition to his research work at the BarcelonaBeta Brain Research Center, Dr. Suárez-Calvet is a clinical neurologist at the Hospital del Mar (Barcelona), specializing in Alzheimer’s disease and other neurodegenerative diseases.
Marc Suárez-Calvet, MD, PhD Neurologist at BarcelonaBeta Brain Research CenterDr. Kiprov’s recent scientific and clinical work focuses on the role of Therapeutic Plasma Exchange (TPE) in the Treatment and Prevention of Age Related Disorders.
Dobri Kiprov, MD, HP Owner at Global ApheresisDr. Alberto Lleó has combined his clinical activity with translational research projects in the field of dementias with a specific focus on the molecular bases of the disease and biomarker development.
Alberto Lleó, MD, PhD Director of the Neurology Department at Hospital de la Santa Creu i Sant PauUniversità degli Studi di Brescia
Andrea PilottoDr. Butler research focusses on understanding the memory deficits experienced by patients with damage to the medial temporal lobes of the brain
Chris Butler, MD, PhD Clinical Senior Lecturer in Neurology at the Imperial CollegeThe Kristel Sleegers lab is committed to increase insight in the complex genetics of Alzheimer’s disease and to investigate the translational potential of genetic discovery.
Kristel Sleegers, MD, PhD Full professor of Genetic Neuroepidemiology at the University of AntwerpThe Neurochemistry Laboratory of VUmc aims at developing biomarkers for neurodegenerative diseases.
Charlotte Teunissen, PhD Professor in Neurochemistry at VUmcDr. Ikram’s research focuses on investigating the etiology of neurologic diseases in the elderly, with a particular focus on dementia, Alzheimer disease, stroke, and Parkinson disease.
Arfan Ikram, MD, PhD Professor and Chair Epidemiology at the Erasmus University Medical CenterHis landmark study on cerebrospinal fluid biomarkers for Alzheimer’s disease from 2006 (Hansson et al, The Lancet Neurology, 2006) has been instrumental for the implementation of these biomarkers in the clinical work-up of Alzheimer’s disease in Sweden and internationally.
Oskar Hansson, MD, PhD Professor of Neurology at Lund UniversityVitorica’s group main goal is the characterization of transgenic mice models of AD at the cellular and molecular levels.
Javier Vitorica, PhD Principal researcher at CibernedDr. Cohen’s research interests include aging, Alzheimer’s disease and neuroimaging.
Ann D Cohen, PhD Associate Professor at the University of PittsburghDr. Hinzen study the structural organization and function of language in the human mind/brain.
Wolfram Hinzen, PhD ICREA Research Professor at UPFDr. Debette studies the specific genetic markers in the structuring of the brain in young adults, using magnetic resonance imaging as part of the i-Share study.
Stéphanie Debette, MD, PhD Professor of Epidemiology and Neurologist at Université de BordeauxDr. Lopez’s clinical interests include cognitive disorders of multiple etiologies, and his research interests include clinical symptoms and progression of Alzheimer’s disease and other dementias, biomarkers, and risk factors for Alzheimer’s disease in cognitively normal persons.
Oscar López, MD Director of the Alzheimer's Disease Research Center at the University of PittsburghDr. Vellas main interests are: development of aging and geriatric clinical research and care.
Bruno Vellas, MD, PhD Department of Geriatric Internal Medicine at the Toulouse University HospitalDr. Sasha Bozeat is responsible for the medical support of the commercially available Elecsys AD CSF assays, as well as the blood-based biomarker pipeline at Roche Diagnostics
Sasha Bozeat, PhD Senior International Medical Manager at Roche DiagnosticsHis research is centered in understanding different aspects of the inflammatory reaction.
Prof. Santos Mañes, PhD Full Professor at the National Center for Biotechnology (CSIC)Prof. Heneka is involved in basic science and translational research with focus on neurodegeneration and neuroinflammation.
Prof. Michael Heneka, MD Director of the Luxembourg Centre for Systems BiomedicineDr. Van der Lee is particularly interested to translate findings from basic science to clinically useful (bio)markers of dementia
Sven van der Lee, MD, PhD Postdoctoral ResearcherDr. Seshadri enjoys a superb reputation in both science and clinical care and is a recognized thought leader in Alzheimer’s disease.
Sudha Seshadri, MD Founding director of the Glenn Biggs Institute for Alzheimer's & Neurodegenerative DiseasesDr. Boada focuses her research on the treatment of AD and related dementias, especially on the genotype and phenotype of common degenerative diseases and the design of new pharmacological and non-pharmacological treatments.
Prof. Mercè Boada, MD, PhD Chief Medical Officer at AceDr. Zlokovic studies the role of brain microcirculation, particularly the blood-brain barrier (BBB) in health and disease in the adult brain and during brain aging.
Berislav V Zlokovic, MD, PhD Director of the Zilkha Neurogenetic InstituteDr. Cano is in charge of the molecular biology unit of Ace Alzheimer Center Barcelona and her studies are related to the clinical evaluation of early biomarkers of Alzheimer’s disease.
Amanda Cano, PhD Postdoctoral researcher at AceThe main objective of his genomic research group is to understand the causes of Alzheimer’s disease and other dementias by integrating genetic, transcriptomic and proteomic data.
Agustín Ruiz, MD, PhD Chief Scientific Officer at AceFocused on translational research with a utility approach to the patient and on providing scientific evidence on the diagnosis in early and preclinical phases of Alzheimer’s disease
Pascual Sánchez Juan, MD, PhD Scientific Director of CIEN FoundationExperience in the cognitive assessment of patients with neurological diseases using different neuropsychological tools, neuroimaging analysis (brain MRI and PET), and in the use of Transcranial Magnetic Stimulation using neuronavigator for the treatment of patients with neurodegenerative diseases.
Vanesa Pytel, MD, PhD Clinical Head of the Diagnostic Unit at AceDr. Alegret has extensive experience in diagnosis, clinical management, neuropsychological evaluation, cognitive stimulation and research on different neurodegenerative diseases
Montse Alegret, PhD Neuropsychologist at AceNeurologist specialist in cognitive disorders with a broad clinical and research experience in Spain and the United States.
Marta Marquié, MD, PhD Neurologist at AceHe has more than 20 years of experience in basic, clinical and applied research in drug dependence, psychopathology and memory disorders.
Sergi Valero, PhD Head of Medical Psychology at Ace Alzheimer Center BarcelonaDr. Villemagne is a physician scientist in full-time research specialising in the development of molecular biomarkers for discovery, diagnosis, prognosis and clinical trials in neurodegenerative diseases.
Victor L Villemagne, MD Professor of Psychiatry at the University of PittsburghSPEAKER’S AREA
Sponsors of the BCNPIT 2022
Don’t miss the opportunity to be part of one of the largest communities in the field of dementia. Join the upcoming XIII Biennial Conference Barcelona Pittsburgh 2024
